USFDA nod to Dr Reddys Lab for VeraRing

USFDA nod to Dr Reddys Lab for VeraRing

189
USFDA
Picture: Pixabay

Last Updated on December 16, 2021 by The Health Master

Hyderabad: Drugmaker, Dr. Reddy’s Labs, has recently announced that the company has received approval from the U.S. Food and Drug Administration (USFDA) for ANDA 207577 (VeraRing).

An abbreviated new drug application (ANDA) contains data that is submitted to the USFDA for review and potential approval of a generic drug product.

Once approved, an applicant may manufacture and market the generic drug product to provide a safe, effective, lower cost alternative to the brand-name drug it references.

Dr. Reddy’s Laboratories Ltd. is an integrated pharmaceutical company headquartered in Hyderabad, Telangana, India. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetes, oncology, pain management, and dermatology.

Dr. Reddy’s operates in markets across the globe. The company’s major markets include – USA, India, Russia, CIS countries, and Europe.

USFDA approves Eye Drops that could replace reading glasses

Zydus Cadila gets USFDA nod for generic Schizophrenia drug

Alembic gets USFDA tentative nod for drug for high BP

Biocon gets USFDA nod for Mycophenolic Acid

Morepen gets USFDA nod for anti-allergy drug

NDPS: 9 arrested for selling drugs

Hindustan Syringes and Medical Devices allowed to restart production

Action sought against Hetero Pharma: HRF

KSRPA asks Govt to amend Rule 123 of D&C Rules w.r.t. Schedule K

USFDA approves Eye Drops that could replace reading glasses

Drug recall: Lupin recalls 4,113 cartons of oral contraceptive

Inquiry needed into unfair trade practice of discount pricing by Medical…

Increase in Pharmacy colleges to meet rising demand of Medical Stores

Procedure for registration of Medical Devices: CDSCO

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news

Enter your email address:

Delivered by FeedBurner